The Joe Rogan Experience #2469 - Brigham Buhler
286 snips
Mar 18, 2026 
Brigham Buhler, founder of Ways2Well and ReviveRx, joins for a fast-moving talk on peptide policy, testosterone myths, and how pharma lobbying shapes access to treatment. They get into GLP-1 battles, preventive care outside insurance, stem cells in states like Texas, AI-driven longevity, gene tweaking, Muse cells, and plasmapheresis.
AI Snips
Chapters
Books
Transcript
Episode notes
Why Buhler Thinks Peptide Policy May Reverse
- Brigham Buhler said peptide access improved because the new HHS and FDA leadership are at least hearing the case instead of stonewalling it.
- He contrasted 17 unanswered FDA FOIA requests under the prior administration with direct meetings involving Robert F. Kennedy Jr., Marty Makary, and Stephanie Spear.
How Testosterone Prostate Fear Became Medical Dogma
- Buhler argued testosterone fear around prostate cancer came from a 1930s three-patient study and persisted as medical dogma.
- He said later practice data and research found no correlation between testosterone therapy and higher prostate cancer prevalence.
Why Peptides Do Not Fit The Drug Approval Machine
- Buhler said peptides clash with FDA logic because they sit outside the insurance and pharma model built for billion-dollar patented drugs.
- He argued cash-pay preventive care needs accessibility, not Medicare coverage, making peptides hard for legacy regulators to categorize.
